Colchicine use might be associated with lower mortality in COVID-19 patients: A meta-analysis
European journal of clinical investigation
BACKGROUND: Colchicine was recently repurposed for the management of coronavirus disease 2019 (COVID-19). This rapid review and meta-analysis aimed to assess colchicine's impact on mortality outcomes in COVID-19 patients. MATERIALS AND METHODS: We systematically searched PubMed, EMBASE, Google Scholar since their inception till 25/03/2021 for observational or controlled studies that reported mortality as an outcome. The mortality odd ratios were generated with their corresponding 95% confidence intervals utilizing the random-effects model. RESULTS: Nine studies comprising 5522 patients met our inclusion criteria. Our meta-analysis revealed significantly lower mortality in the colchicine group (OR 0.35, 95% CI 0.25-0.48, I2 0%) compared with controls. A subgroup analysis limited to hospitalized patients (OR 0.35, 95% CI 0.25-0.50, I2 0%) revealed similarly lower mortality in the colchicine group. CONCLUSIONS: This meta-analysis suggests a mortality benefit with colchicine when used in the treatment of COVID-19 patients. The majority of included studies were observational; thus, the findings of this review need to be further supported by the results of ongoing trials.
Elshafei, Mohamed Nabil; El-Bardissy, Ahmed; Khalil, Ahmed; Danjuma, Mohammed; Mubasher, Mahmood; Abubeker, Ibrahim Y.; and Mohamed, Mouhand F., "Colchicine use might be associated with lower mortality in COVID-19 patients: A meta-analysis" (2021). Rochester Regional Health authored publications and proceedings. 354.